Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 3 1

Status

Completed 67Terminated 21Recruiting 21Unknown 17Active not recruiting 16Not yet recruiting 6Withdrawn 3Enrolling by invitation 1Approved for marketing 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Lymphoid 2Plasma cell 1

Conditions

Breast Neoplasms 21Lymphoma 18Lymphoma, Large B-Cell, Diffuse 15Leukemia, Myeloid, Acute 14Precursor Cell Lymphoblastic Leukemia-Lymphoma 13Lymphoma, Non-Hodgkin 12Lymphoma, Follicular 12Leukemia, Lymphocytic, Chronic, B-Cell 12Multiple Myeloma 11Burkitt Lymphoma 11Leukemia 10Lymphoma, Mantle-Cell 9Myelodysplastic Syndromes 8Melanoma 8Lymphoma, B-Cell, Marginal Zone 7Triple Negative Breast Neoplasms 6Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 6Ovarian Neoplasms 6Hodgkin Disease 6Carcinoma, Non-Small-Cell Lung 6Lymphoma, Large-Cell, Anaplastic 5Leukemia, Myelogenous, Chronic, BCR-ABL Positive 5Hematologic Neoplasms 5Waldenstrom Macroglobulinemia 4Sezary Syndrome 4Sarcoma 4Mycosis Fungoides 4Lymphoma, T-Cell, Cutaneous 4Lymphoma, Large-Cell, Immunoblastic 4Leukemia, Myeloid, Chronic-Phase 4

Interventions

Dexamethasone 14Rituximab 6Cytarabine 5venetoclax 4Lenalidomide 4Bortezomib 4Bendamustine Hydrochloride 4selinexor 3pomalidomide 3pembrolizumab 3ibrutinib 3fludarabine 3carfilzomib 3Paclitaxel 3Gemcitabine 3Drug Therapy 3Cyclophosphamide 3Calcium Dobesilate 3ixazomib 2gilteritinib 2fludarabine phosphate 2elotuzumab 2daratumumab 2belinostat 2Tablets 2Surveys and Questionnaires 2Panobinostat 2Oxaliplatin 2Granulocyte Colony-Stimulating Factor 2Etoposide 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Withdrawn × Recurrence × Cyclophosphamide × Clear all
NCT06313996 2026-03-18

A Study to Evaluate the Efficacy and Safety of Liso-cel Compared to Standard of Care in Adults With Relapsed or Refractory Follicular Lymphoma

Juno Therapeutics, Inc., a Bristol-Myers Squibb Company

Phase 3 Withdrawn
Lymphoid

Lymphoma, Follicular, Recurrence

NCT02985333 2018-05-14

Paclitaxel,Cyclophosphamide and Dexamethasone for Relapsed or Refractory Multiple Myeloma

Sun Yat-sen University

Phase 2 Withdrawn
Plasma cell

Multiple Myeloma, Recurrence

NCT00801918 2013-05-15

Denileukine Diftitox for Relapsed ALCL

Columbia University

Phase 2 Withdrawn
Lymphoid

Lymphoma, Recurrence, Lymphoma, Large-Cell, Anaplastic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡